~~<i id='4907185D42'><strike id='4907185D42'><tt id='4907185D42'><pre id='4907185D42'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：focus 2025-10-01 23:51:42 Page View：289

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

comprehensive

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Whatmakesablockbuster?CanbiotechlearnfromAduhelm?Andhowdoyoureplaceasingularregulator?Wecoverallthat

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Surgeonspreparethegene-editedpigkidneyfortransplantationatMassachusettsGeneralHospital.Massachusetts